MAY 29, 2015 8:00 AM PDT

Lupus Anticoagulant Testing Made Simple

Sponsored by: Diagnostica Stago, Inc.
  • Scientific Business Development Manager, Diagnostica Stago, Inc.
      Paul earned a PhD in biochemistry from Temple University in 2006, with the subject of the dissertation regarding the function of coagulation factor XI. He also did postdoctoral training in a related area before becoming a product manager and scientific affairs specialist in 2009. During his time at Stago, Paul also completed an MBA degree program at Cornell University in 2014. He has spoken to dozens of medical technologist, clinical laboratory scientist, pharmacist and clinician audiences about various topics within hemostasis and coagulation. He also has a great interest in working with clinical pathologists, pharmacists, basic scientists, and pharmaceutical researchers to perform studies and publish, contributing to advancement of the hemostasis and coagulation science.


    Lupus anticoagulants occur in patients, increase their risk of thrombosis and may or may not be associated with other disease states such as systemic lupus erythematosus (SLE).  Detection of lupus anticoagulants and confirmed diagnosis of associated antiphospholipid syndrome (aPS) requires use of multiple assays utilizing clotting as well as solid phase methodology, along with confirmation of the clinical etiology.  The purpose of this program is to update healthcare professionals regarding advancements in aPS and LA testing. Current LA diagnostic guidelines, additional aPS testing, clinical evidence regarding LA testing methodologies, and case studies will be presented.

    • Describe antiphospholipid syndrome (aPS) and the role of lupus anticoagulant (LA) in thrombosis.
    • Present current guidelines for LA screening and confirmation.
    • Discuss recommended LA testing methodologies.
    • Correlate LA and aPS to specific clinical cases.

    Show Resources
    Show Resources
    • See more
    Connect with us